Comparing the newest fluoroquinolones: Levofloxacin and sparfloxacin

Formulary

Volumn 32, Issue 9, 1997, Pages 926-943

  Beringer, Paul M ^a   Holtom, Paul D ^b   Rho, Jay P ^c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d USC UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; PHASE 3 CLINICAL TRIAL; PHOTOTOXICITY; QT INTERVAL; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; SKIN INFECTION; URINARY TRACT INFECTION;

EID: 0030766919     PISSN: 00986909     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Levaquin (levofloxacin) package insert. Raritan, NJ: Ortho Pharmaceutical Corp, December 1996.
2. Miyamoto T, Matsumoto J, Chiba K, et al. Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. J Med Chem 1990; 33:1645-56.
3. Zagam (sparfloxacin) package insert. Collegeville, PA: Rhone-Poulenc Rorer Pharmaceuticals, Inc, January 1997.
4. Eliopoulos GM, Wennersten CB, Moellering RC Jr. Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria. Diagn Microbiol Infect Dis 1996;25:35-41.
5. Yamane N, Jones RN, Frei R, et al. Levofloxacin: In vitro results from an international study with ofloxacin and ciprofloxacin. J Chemotherapy 1994;6:83-91.
6. Baltch AL, Smith RP, Franke MR, et al. Antibacterial effect of levofloxacin, erythromycin and rifampin in a human monocyte system against Legionella pneumophilia [abstract No. E67]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
7. Cormican MG, Erwin ME, Marshall SA, et al. Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis. Diagn Microbiol Infect Dis 1996;24:155-60.
8. Cohen MA, Yoder SL, Talbot GH. Sparfloxacin worldwide in vitro literature: Isolate data available through 1994. Diagn Microbiol Infect Dis 1996;25:53-64.
9. Tanigawara Y, Nomura H, Kagimoto N, et al. Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Biol Pharm Bull 1995; 18:315-20.
10. Child J, Mortiboy D, Andrews JM, et al. Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother 1995;39:2749-51.
11. Chien SC, Chow AT, Fowler CL, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750 mg and 1 g doses of levofloxacin in healthy volunteers [abstract No. A14]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
12. Montay G. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: A review. J Antimicrob Chemother 1996;37(Suppl A):27-39.
13. Wise R, Honeybourne D. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J Antimicrob Chemother 1996;37(Suppl A):57-63.
14. Gisclon LG, Curtin CR, Williams RR, et al. The pharmacokinetics of levofloxacin in subjects with renal impairment, and in subjects receiving hemodialysis or continuous ambulatory peritoneal dialysis [abstract No. A13]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18,1996; New Orleans.
15. Preston SL, Drusano, GL, Herman AL, et al. Prospective development of pharmacodynamic relationships between measures of levofloxacin exposure and measures of patient outcome [abstract No. A98]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
16. Dorr MB, Pentikis HS, Johnson RD, et al. Pharmacokinetics/pharmacodynamics of clinical and bacteriologic response in patients receiving sparfloxacin during North American Phase III clinical trials [abstract No. LM14]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
17. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of IV/PO levofloxacin vs ceftriaxone/cefuroxime axetil in the treatment of adults with community-acquired pneumonia [abstract No. LM1]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
18. Henry D, Stein W, Bensch G, et al. Treatment of community-acquired pneumonia with sparfloxacin and erythromycin [abstract No. LM12]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
19. Branditz F, Salisbury J, Brandon M, et al. Treatment of community-acquired pneumonia with sparfloxacin and cefaclor [abstract No. LM10]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
20. Adeglass J, Deabate AC, Mcelvaine P, et al. A comparison of levofloxacin qd and amoxicillin-clavulanate tid for the treatment of acute bacterial sinusitis [abstract No. 290]. 34th Annual Meeting Infectious Diseases Society of America, Sept 18-20, 1996; New Orleans.
21. Henry D, Moller D, Adelglass J, et al. Treatment of acute bacterial maxillary sinusitis with sparfloxacin and clarithromycin [abstract No. LM8]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
22. DeAbate CA, Russell M, Mcelvaine, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1997;42:206-13.
23. Habib MP, Gentry LO, Rodriguez-Gomez G, et al. A multicenter randomized study comparing the efficacy and safety of oral levofloxacin vs. cefaclor in the treatment of acute bacterial exacerbations of chronic bronchitis [abstract No. LM2]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
24. Allegra L, Konietzko N, Leophonte P, et al. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A double-blind, randomized, parallel, multicentre study. J Antimicrob Chemother 1996;37(Suppl A):93-104.
25. DeAbate CA, Henry D, Bensch G, et al. Treatment of acute bacterial exacerbations of chronic bronchitis with sparfloxacin and ofloxacin [abstract No. LM9]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
26. Nichols R, Smith J, Gentry LO, et al. Multicenter, open-label, active-controlled, randomized comparison of levofloxacin qd vs ciprofloxacin hid in 469 adults with mild to moderate skin and skin structure infections [abstract No. 288]. 34th Annual Meeting Infectious Diseases Society of America, Sept 18-20, 1996; New Orleans.
27. Miller B, Schwartz R, Henry D, et al. Treatment of community-acquired complicated skin and skin structure infections with sparfloxacin and ciprofloxacin [abstract No. LM11]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
28. Richard GA, Childs S, Fowler C, et al. A comparison of levofloxacin and ciprofloxacin for the treatment of complicated urinary tract infections [abstract No. 293] 34th Annual Meeting Infectious Diseases Society of America, Sept 18-20, 1996; New Orleans.
29. Richard GA, Klimberg IN, Fowler CL, et al. A combined analysis of two studies comparing levofloxacin with two other fluoroquinolones for the treatment of acute pyelonephritis [abstract No. LM3]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
30. Henry D, Nenad R, Iravani A, et al. Treatment of community-acquired acute uncomplicated urinary tract infections with sparfloxacin and ciprofloxacin [abstract No. LM6]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
31. Henry D, Ellison W, Sullivan J, et al. Treatment of community-acquired acute uncomplicated urinary tract infections with sparfloxacin and ofloxacin [abstract No. LM7]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 15-18, 1996; New Orleans.
32. Moi H, Morel P. Gianotti B, et al. Efficacy and safety of single oral dose sparfloxacin vs ciprofloxucin in acute gonococcal urethritis in males. Drugs 1995; 49(Suppl 2):387-9.
33. Lipsky BA, Dorr MB, Magner DJ, et al. Safety profile of sparfloxacin in North American phase III clinical trias[abstract No. LM13]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Sept 15-18, 1996; New Orleans.
34. Christ W. Central nervous system toxicity of quinolones; human and animal findings. J Antimicrob Chemother 1990;26:219-25.
35. Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulfate, and ranitidine on absorption of dr-3355 in humans. Antimicrob Agents Chemother 1992;36:2270-74.
36. Yamaki K, Miyatake H, Taki F, et al. Studies on sparfloxacin (SPFX) against respiratory tract infections and its effect on theophylline pharmacokinetics. Chemotherapy 1991;39:280-5.
37. Drug Topics Red Book. Montvale NJ: Medical Economics Data Inc; 1997.